Month: February 2024

Gentex’s HomeLink Brand Expands To Provide Smart Home & Security Systems

Written by Customer Service on February 27, 2024. Posted in Public Companies.

ZEELAND, Mich., Feb. 27, 2024 (GLOBE NEWSWIRE) — Today at the International Builders’ Show, Gentex Corporation (NASDAQ: GNTX) announced the launch of HomeLink Smart Home Solutions, a comprehensive, curated suite of smart home products all controlled and monitored by a single app. The overall goal is to help unite the worlds of car connectivity and home automation into a single, seamless ecosystem. Gentex is a technology company and a long-time supplier of electro-optical products for the global automotive, aerospace, fire protection, and medical industries. It’s best known for supplying nearly every major automaker with connected-car technologies and advanced electronic features that optimize driver vision and enhance driving safety. Gentex’s HomeLink product is the auto industry’s leading car-to-home automation system, consisting...

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Written by Customer Service on February 27, 2024. Posted in Public Companies.

WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a panel entitled “Gynecological Cancers Corporate Panel Discussion” on Tuesday, March 5, 2024 at 10:30 a.m. ET at the TD Cowen 44th Annual Health Care Conference in Boston, MA. To access the live webcast, visit the Events & Presentations page within the investor section...

Lancaster Resources Acquires High-Impact Uranium Claims in Athabasca Basin

Written by Customer Service on February 27, 2024. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR) (OTCQB:LANRF) (FRA:6UF) (“Lancaster”), Lancaster Resources, a North American critical minerals exploration company, is excited to announce the acquisition of two high impact mineral claims in the world-class Athabasca Basin. The two claims are targeting high grade uranium in basement and unconformity type deposits. The two properties, called Catley Lake and Centennial East, at 3,036 hectares and 5,081 hectares respectively, provide significant exploration opportunities. These strategic acquisitions bolster Lancaster’s commitment to discovering critical minerals in support of the energy transition. The Catley Lake & Centennial East mineral claims are located immediately adjacent to Cameco’s Centennial deposit claim block in...

Volaris Acquires Zeit AG

Written by Customer Service on February 27, 2024. Posted in Mergers And Acquisitions.

Provides time-tracking software to address complex strategic, operational, and regulatory requirements TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Volaris Group, a global leader in vertical market software, today proudly announced its acquisition of Zeit AG, a provider of workforce management solutions catering to the needs of complex European organizations. Zeit’s technology helps customers address time tracking for employees and projects, workforce and shift planning, and attendance management requirements. Commenting on the acquisition, Alice Luo, Chief Strategy Officer at Volaris Group said, “I look forward to working with Zeit AG to continue to deliver increasing value to their customers and supporting its mission to deliver new time tracking and workforce management innovation. Volaris best practices and learning opportunities...

Sotera Health Reports Fourth-Quarter and Full-Year 2023 Results; Provides 2024 Outlook

Written by Customer Service on February 27, 2024. Posted in Earnings Releases And Operating Results.

2023 net revenues increased 4.5% to $1.05 billion, compared to 2022 2023 net income of $51 million or $0.18 per diluted share 2023 Adjusted EBITDA(1) increased 4.3% to $528 million 2023 Adjusted EPS(1) decreased $0.15 to $0.81 per diluted share Full-year 2024 outlook of 4.0% – 6.0% growth for Net Revenues and Adjusted EBITDACLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2023 and its initial 2024 outlook. For the fourth-quarter 2023, net revenues increased 23.3% to $310 million, compared with $252 million in the same period a year ago. Net...

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on February 27, 2024. Posted in Earnings Releases And Operating Results.

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending further data and discussions with regulatory authorities, the expanded development plan for vepdegestrant will include a new Phase 3 trial in combination with CDK4/6 inhibitors in the second-line setting and a new Phase 3 trial of vepdegestrant plus Pfizer’s novel CDK4 inhibitor in the first-line setting – – Prioritized second-generation PROTAC® AR degrader ARV-766 after updated data showed robust efficacy in tumors with all AR LBD mutations in mCRPC – – Received regulatory clearance to initiate first-in-human Phase 1 clinical trials for PROTAC® targeting BCL6...

AGF Investments Launches Additional ETF Series

Written by Customer Service on February 27, 2024. Posted in Public Companies.

Offerings provide investors with access to alternatives, active fixed income, and U.S. small-mid cap equities in a mutual fund with ETF series option TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) announced that effective today it is expanding its line-up with the launch of ETF series options for AGF Global Real Assets Fund, AGF Total Return Bond Fund and AGF U.S. Small-Mid Cap Fund. “We continue to broaden our ETF offerings with the addition of ETF series options on long-running funds in key areas of focus for investors, including alternative assets and active fixed income,” said Meaghan Kelly, Chief Marketing & Product Officer, AGF Investments. “This launch builds on our commitment to provide options for our investors to access our capabilities in any of their preferred vehicles.”Fund...

Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

Written by Customer Service on February 27, 2024. Posted in Public Companies.

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it had a pre-investigational new drug application (PIND) meeting with the U.S. Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products (DCRP) on February 23, 2024 to discuss Arch’s plan to repurpose cilastatin as a new treatment to prevent toxin related acute kidney injury (AKI). Currently, there are no specific treatments for the prevention or treatment of AKI. Arch has the opportunity to sponsor a Phase II trial for cilastatin in toxin-related AKI targeting either nephrotoxic drug and/or rhabdomyolysis-associated AKI (explained further below). The PIND meeting provided the Arch team with guidance from the FDA for the content of a future IND application for...

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Written by Customer Service on February 27, 2024. Posted in Earnings Releases And Operating Results.

Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation for BEAM-302 in Alpha-1 Antitrypsin Deficiency on Track for First Half of 2024 Pending European Clinical Trial Application (CTA) Acceptance Ended Fourth Quarter 2023 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported fourth quarter and full year 2023 financial results and reiterated anticipated milestones across the company’s sickle cell disease and genetic disease portfolios. “This...

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Written by Customer Service on February 27, 2024. Posted in Earnings Releases And Operating Results.

– Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application to the European Medicines Agency for nirogacestat for the treatment of desmoid tumors – – Presented positive topline data from Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN; on track to submit New Drug Application in first half of 2024 – – Submitted IND for SW-682 and received FDA clearance to proceed with Phase 1a trial – – Ended 2023 with $662.6 Million in Cash, Cash Equivalents and Marketable Securities – STAMFORD, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial...

Month: February 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals